Why the study?
Does fondaparinux reduce death or MI in STEMI patients receiving thrombolytic therapy?
Does fondaparinux reduce death or MI in STEMI patients receiving thrombolytic therapy?
In STEMI patients treated with thrombolytic agents, fondaparinux significantly reduces the risk of death, reinfarction, and severe bleeding at 30 days.
No takes yet. Share an insight, caveat, or question.
Supports fondaparinux with thrombolysis in STEMI; confirms adjunctive anticoagulation benefit on death or MI.
Peters et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: